Folate Receptor Alpha Results Explained

IHC scoring, ovarian cancer and mirvetuximab eligibility

What each line of the report means

Specimen: Tumor tissue, as stated
Folate receptor alpha is assessed by immunohistochemistry on tissue, not on blood.
Assay: FOLR1 IHC, defined clone
The scoring system is tied to a specific validated antibody clone; results from other clones are not interchangeable.
Biomarker / finding: Positive, high expression
Eligibility for folate-receptor-directed therapy depends on meeting a defined staining threshold, not on any positive stain.
Quantitative result: Percentage of tumor cells with membrane staining at a stated intensity
Both the proportion of cells and the intensity are part of the result.
Clinical interpretation: Cancer-specific review required
The result is used mainly in platinum-resistant ovarian, fallopian tube and primary peritoneal cancer.

How this result is interpreted

  • Folate receptor alpha is overexpressed in a large share of ovarian cancers, which is why it became a drug target rather than only a descriptive marker.
  • The result matters most in platinum-resistant ovarian, fallopian tube and primary peritoneal cancer, where it determines access to folate-receptor-directed antibody-drug conjugate therapy.
  • A result described as low or negative does not mean the tumor lacks options; it means this particular pathway is not the route.

What this result cannot tell you

  • Expression can differ between the primary tumor and a later metastatic sample, and between blocks from the same surgery.
  • Scoring depends on the antibody clone, the laboratory's validation and the pathologist's read, so an outside review sometimes changes the call.
  • A qualifying score establishes biomarker eligibility only; prior therapy, platinum status, eye health and organ function still determine whether treatment proceeds.

Questions to ask your oncologist

  • Which antibody clone and scoring threshold did the laboratory use, and did my result meet it?
  • Which specimen was tested, and how old is it relative to my current disease?
  • If my result was borderline, is retesting on a more recent sample reasonable?
  • Does this result open a licensed treatment now, or a clinical trial?
  • What monitoring would be needed if folate-receptor-directed therapy is used?

Frequently asked questions

Does a positive stain automatically mean I qualify for treatment?

No. Eligibility depends on meeting the defined scoring threshold for the validated assay, and then on the clinical situation: cancer type, platinum sensitivity, prior lines of therapy and organ function.

Can the result change over time?

Expression is measured on one specimen at one moment. Tumors evolve under treatment, so a sample taken years earlier may not represent current disease. The specimen date on the report matters.

Can someone independently review this result?

Yes. A Clarity Report can assess the assay used, the score, the specimen, prior treatment and current trial relevance, then return the findings in writing.

Sources

Free 15-minute consultation